Generic Name and Formulations:
Estazolam 1mg, 2mg; scored tabs.
Various generic manufacturers
Indications for Estazolam:
Short-term treatment of insomnia.
Initially 1mg at bedtime. May increase to 2mg nightly. Small or debilitated elderly: initially 0.5mg.
<18yrs: not recommended.
Concomitant ketoconazole, itraconazole. Pregnancy (Cat.X).
Drug or alcohol abuse. Suicidal tendencies. Depression. Renal, hepatic, or respiratory impairment. Avoid abrupt cessation after prolonged use. Elderly. Debilitated. Nursing mothers: not recommended.
Potentiates CNS depression with alcohol, other CNS depressants. Caution with CYP3A inhibitors (eg, nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazid, other macrolides): consider dose reduction.
CNS depression, complex sleep-related behaviors (eg, sleep-driving), hypokinesia, dizziness, incoordination, confusion, constipation, anxiety, paradoxical excitement; anaphylaxis, angioedema.
Formerly known under the brand name Prosom.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|